Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 4;29(1):63-74.
doi: 10.3727/096504022X16462176651719. Epub 2022 Mar 2.

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations

Yudie Yang  1 , Xia Zhang  2 , Yajie Gao  1 , Yan Dong  1 , Di Wang  1 , Yanping Huang  1 , Tianhao Qu  1 , Buqun Fan  1 , Qizheng Li  1 , Chunxia Zhang  1 , Xiaonan Cui  1 , Bin Zhang  1
Affiliations

Research Progress in Immunotherapy of NSCLC With EGFR-Sensitive Mutations

Yudie Yang et al. Oncol Res. .

Abstract

Lung cancer is a malignant tumor with high incidence and mortality across the world. The use of immune checkpoint inhibitors for lung cancer has improved the prognosis of some lung cancer patients to a greater extent and provided a new direction for the clinical treatment of lung cancer. Immunotherapy still has limitations in terms of its appropriate population and adverse reactions. Particularly for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation, there has been no major breakthrough in current immunotherapy. Whether immunotherapy can bring new benefits after drug resistance is induced by tyrosine kinase inhibitor-targeted therapy and whether the combination of immunotherapy with other treatments can improve the prognosis remain to be studied in depth. In this article, we provide a detailed review of the relevant characteristics of the tumor microenvironment of NSCLC with EGFR mutation and the current research on immunotherapy for NSCLC with EGFR mutation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Graphical summary for the text.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Soerjomataram I, Jemal A, Bray F. 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249. - PubMed
    1. Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, Gu XY, Wei WW, He J. 2019. [Report of cancer epidemiology in China, 2015]. Zhonghua Zhong Liu Za Zhi. 41(1):19–28 [Chinese]. - PubMed
    1. Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, Wang N, Han R, Liu S, Li H, Mu H, He Y, Xu Y, Fu Z, Zhou Y, Jiang J, Yang Y, Chen J, Wei K, Fan D, Wang J, Fu F, Zhao D, Song G, Chen J, Jiang C, Zhou X, Gu X, Jin F, Li Q, Li Y, Wu T, Yan C, Dong J, Hua Z, Baade P, Bray F, Jemal A, Yu XQ, He J. 2018. Changing cancer survival in China during 2003–15: A pooled analysis of 17 population-based cancer registries. Lancet Glob Health 6(5):e555–e567. - PubMed
    1. He J, Li N, Chen WQ, Wu N, Shen HB, Jiang Y, Li J, Wang F, Tian JH. 2021. Consulting Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer; Expert Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer; Working Group of China Guideline for the Screening and Early Diagnosis and Treatment of Lung Cancer. [China guideline for the screening and early detection of lung cancer (2021, Beijing)]. Zhonghua Zhong Liu Za Zhi 43(3):243–268. - PubMed
    1. Pinto JA, Vallejos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS, Morante Z, Araujo JM, Gómez HL, Aguilar A, Bretel D, Flores CJ, Rolfo C. 2018. Gender and outcomes in non-small cell lung cancer: An old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open 3(3):e000344. - PMC - PubMed